This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
ALNYNegative Net Change NVSNegative Net Change PFENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
by Zacks Equity Research
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
QURENegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
by Zacks Equity Research
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
BEAMNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
by Zacks Equity Research
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
PFENegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs medical pharmaceuticals vaccines
Denali to Sell Priority Review Voucher for $195M Cash Boost
by Zacks Equity Research
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
SNYNegative Net Change BIIBPositive Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
by Zacks Equity Research
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
MRNANegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
by Zacks Equity Research
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
RHHBYNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Surges 35% in Six Months: What's Driving It?
by Zacks Equity Research
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
AGIONegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
by Zacks Equity Research
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
JAZZNegative Net Change LQDANegative Net Change ABCLNegative Net Change IMCRNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
by Ahan Chakraborty
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals